FERA-Q Tablets: Helps to Support the Treatment of Cancer Induced Anaemia in Patients Undergoing Chemotherapy and Radiation Therapy

Cancer-induced anemia is most common in patients with cancer and in patients undergoing chemotherapy and radiation therapy. The severity of anemia depends on the extent of disease and the density of treatment. Repeated cycles of chemotherapy may impair erythropoiesis synthesis that results in decrease functional capacity and quality of life. In cancer patients, the incidence of anemia may rise 40%.According to European cancer anemia survey (ECAS) 53% of patients did not receive any treatment for their anemia. Anemia has also been identified as an adverse prognostic factor for these patients. Thus Anemia exerts a negative influence on the quality of life of cancer patients as it may contribute to cancer-induced fatigue. This article reviews the current available scientific literature regarding the effect of FERA-Q tablets to support the treatment of Cancer induced Anaemia in patients.

Keywords: FERA-Q tablets, Cancer induced Anaemia.

Barrett-Lee, P. J., A., et al. (2006).Independent risk factors for anemia in cancer patients receiving chemotherapy: Results from the European cancer anaemia survey. Oncology, 70(1), 34-48.

M. Dicato, L. Plawny& M. Diederich. Anemia in cancer. Annals of Oncology 21 (Supplement 7): vii167–vii172, 2010.

Jerome E. Groopman, Loretta M. Itri.Chemotherapy-Induced Anemia in Adults:Incidence and Treatment. Journal of the National Cancer Institute, Vol. 91, No. 19, October 6, 1999.

Gianni L, Munzone E, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995;13:2688–99.

Figueredo AT, Hryniuk WM, Strautmanis I, Frank G, Rendell S. Cotrimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 1985;3:54–64.

Linus Pauling Institute. Zinc. http://lpi.oregonstate.edu/infocenter/minerals/ zinc/. Updated March 14, 2011. Accessed July 24, 2012.

Truong-Tran AQ, Ho LH, Chai F, Zalewski PD. Cellular zinc fluxes and the regulation of apoptosis/gene-directed cell death. J Nutr. 2000;130(5S Suppl):1459S-1466S.

O'Dell BL. Role of zinc in plasma membrane function. J Nutr. 2000;130(5S Suppl):1432S-1436S.

Ji-Yong Liang, Yi-Yan Liu. Inhibitory Effect of Zinc on Human Prostatic Carcinoma Cell Growth. Prostate. 1999 August 1; 40(3): 200–207.

Peck, A., Graff, D.J., 1973. The absorption and metabolism of hot zinc chloride versus hot zinc amino acid chelate. 

Xue-Hong Zhang, et.al.Vitamin B6 and colorectal cancer: Current evidence and future directions. World J Gastroenterol 2013 February 21; 19(7): 1005-1010.

F. Aguilar, U.et.al. SCIENTIFIC OPINION on 5’-deoxyadenosylcobalamin and methylcobalamin as sources for Vitamin B12 added as a nutritional substance in food supplement. The EFSA Journal (2008) 815, 1-21.

Davis CD1, Uthus EO.DNA methylation, cancer susceptibility, and nutrient interactions. Exp Biol Med (Maywood). 2004 Nov; 229(10):988-95.

Ximena Duque1, Homero Martinez,et.al. Effect of supplementation with ferrous sulfate or iron bis-glycinate chelate on ferritin concentration in Mexican schoolchildren: a randomized controlled trial.

Ferrari P1, Nicolini A, et.al Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: comparison between oral ferrous bisglycinate chelate and ferrous sulfate. Biomed Pharmacother. 2012 Sep; 66(6):414-8.

Liang JY1, Liu YY, et.al. Inhibitory effect of zinc on human prostatic carcinoma cell growth. Prostate. 1999 Aug 1; 40(3):200-7.